Use of Loperamide as a Phenotypic Probe of mdr1a Status in CF-1 Mice
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Purpose. A subpopulation of the CF-1 mouse strain (approximately 25%) lacks P-gp expression, and consequently, increased brain penetration of many substrates is observed in these animals. Mice lacking the mdr1a gene represent an important research tool to study the potential effects of P-gp on CNS substrate disposition.
Methods. Adult CF-1 mice were used in all experiments. Loperamide-induced antinociception was determined by the hotplate latency test at 0.25, 2, and 4 h post-dose. At the conclusion of the pharmacodynamic experiment(s), trunk blood and brain tissue were collected and analyzed by high-performance liquid chromatography-mass spectrometry (LC-MS/MS). Mice were also genotyped for their mdr1a status via RT-PCR.
Results. All mice with three consecutive effects of maximum hotplate latency (60 s) showed considerable opioid-like behavior in addition to antinociception. Mice without three consecutive effects of maximum hotplate latency (≤30 s) showed no opioid-like behavior. The loperamide brain-to-serum ratio in mice identified as P-gp-deficient was 65-fold higher compared to the P-gp-competent animals (10.1 ± 1.0 vs. 0.155 ± 0.018). All animals identified as phenotypically P-gp-competent based on the hotplate assay evidenced the mdr1a(+/+) genotype.
Conclusion. This assay appears to offer a rapid and unambiguous measure via a relatively non-invasive, simple technique to identify P-gp status in the CF-1 subpopulation of mice.
- Juliano, R. L., Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Bio-chim. Biophys. Acta 455: pp. 152-162
- Golden, P. L., Pollack, G. M. (2003) Blood-brain barrier efflux trans-port. J. Pharm. Sci. 92: pp. 1739-1753
- Ling, V. (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40: pp. S3-S8
- Juranka, P. F., Zastawny, R. L., Ling, V. (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3: pp. 2583-2592
- Umbenhauer, D. R., Lankas, G. R., Pippert, T. R., Wise, L. D., Cartwright, M. E., Hall, S. J., Beare, C. M. (1997) Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146: pp. 88-94
- Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H>, Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., Berns, A. J., Borst, P. (1994) Disruption of the mouse mdr1ap-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased senstivity to drugs. Cell 77: pp. 491-502
- Borst, P., Schinkel, A. H., Smit, J. J. M., Wagenaar, E., van Deemter, L., Smith, A. J., Eijdems, E. W. H. M., Baas, F., Zaman, G. J. R. (1993) Classical and novel forms of multidrug resistance and the physiological functions of p-glycoproteins in mammals. Phamac. Ther. 60: pp. 289-299
- Narita, M., Suzuki, T., Misawa, M., Nagase, H. (1993) Antagonism of the morphine-induced Straub tail reaction by k-opioid receptor activation in mice. Psychopharmacology 110: pp. 254-256
- Chen, C., Pollack, G. M. (1997) Blood-brain disposition and antino-ciceptive effects of-D-penicillamine2,5-enkephalin in the mouse. J. Pharmacol. Exp. Ther. 283: pp. 1151-1159
- Pippert, T. R., Umbenhauer, D. R. (2001) The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral in-sertion in the mdr1a gene. J. Biochem. Mol. Toxicol. 15: pp. 83-89
- Schinkel, A. H., Wagenaar, E., Mol, C. A., van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97: pp. 2517-2524
- Sadeque, A. J., Wandel, C., He, H., Shah, S., Wood, A. J. (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68: pp. 231-237
- Pauli-Magnus, C., Feiner, J., Brett, C., Lin, E., Kroetz, D. L. (2003) No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. 74: pp. 487-498
- Skarke, C., Jarrar, M., Schmidt, H., Kauert, G., Langer, M., Geisslinger, G., Lotsch, J. (2003) Effects of ABCB1 (multidrug resis-tance transporter) gene mutations on disposition and central ner-vous effects of loperamide in healthy volunteers. Pharmacogenet-ics 13: pp. 651-660
- Lankas, G. R., Cartwright, M. E., Umbenhauer, D. (1997) P-glycoprotein deficiency in a subpopulation of CF-1 mice en-hances avermectin-induced neurotoxicity. Toxicol. Appl. Phar-macol. 143: pp. 357-365
- Use of Loperamide as a Phenotypic Probe of mdr1a Status in CF-1 Mice
Volume 21, Issue 10 , pp 1867-1870
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- CF-1 mice
- Industry Sectors